tirzepatide maximum weight loss surmount trials for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Tirzepatide as Compared with Semaglutide

Semaglutide, a GLP-1 receptor agonist found in Ozempic, helps control blood sugar by promoting the synthesis of insulin, decreasing the livers release of glucose, and delaying the intestinal absorption of sugar

It is not approved, and is not intended, for diagnosis, treatment, cure, or prevention of any disease in humans or animals

Crash and dependence : Energy crashes when effects wear off

Gi c th thay i theo thi im, bn nn lin h c bo gi chnh xc

2024 DOI: 10.1038/s41421-024-00702-y PMID: 39019866 Read on PubMed European Journal of Clinical Pharmacology A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Kaur M, Misra S 2024 DOI: 10.1007/s00228-024-03646-0 PMID: 38367045 Read on PubMed Cardiology in Review The First Triple Agonist for Antiobesity: Retatrutide Tetelbaum L, Mullally JA, Frishman WH 2024 DOI: 10.1097/CRD.0000000000000793 PMID: 39724554 Read on PubMed NPJ Metabolic Health and Disease Incretin triple agonist retatrutide alleviates obesity-associated cancer progression Marathe SJ, Grey EW, Bohm MS, et al